Dr. Brown is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
# Dana-Far
Boston, MA 02115Phone+1 617-632-4894Fax+1 617-582-7909
Education & Training
Brigham and Women's HospitalResidency, Internal Medicine, 2017- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2004
Massachusetts General HospitalResidency, Internal Medicine, 1998 - 2001
Harvard Medical SchoolClass of 1998
Certifications & Licensure
MA State Medical License 2000 - 2026
MS State Medical License 2017 - 2021- American Board of Internal Medicine Hematology
Clinical Trials
- Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma Start of enrollment: 2003 Dec 01
- Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma Start of enrollment: 2005 Feb 01
- Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies Start of enrollment: 2004 Aug 09
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsASCT in follicular lymphoma.Jennifer R. Brown, Arnold S. Freedman
Nature Reviews. Clinical Oncology. 2009-07-01 - 64 citationsAssociation of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia.Nicole F. Velez, Pritesh S. Karia, Alexander R. Vartanov, Matthew S. Davids, Jennifer R. Brown
JAMA Dermatology. 2014-03-01 - 205 citationsMitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid MalignanciesRomain Guieze, Vivian M. Liu, Daniel Rosebrock, Alexis A. Jourdain, María Hernández-Sánchez
Cancer Cell. 2019-10-14
Abstracts/Posters
- Imbalance in T Cell Subsets Triggers the Autoimmune Toxicity of PI3K Inhibitors in CLLJennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inh...Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with InvestigatorÍs Choice of ...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na¥ve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Press Mentions
ASH 2022: New Findings in CLLDecember 28th, 2022- High Frequency of Germline ATM Variants in CLLNovember 11th, 2022
Clinical Challenges: Selecting First-Line Therapy in CLLMay 20th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
